Teva and Fosun Pharma partner on early-stage oncology drug
Pharma Times
JUNE 18, 2025
The drug is being evaluated as both a monotherapy and in combination with Merck & Co’s Keytruda (pembrolizumab) for cancers such as melanoma, after demonstrating tumour regression, enhanced T-cell infiltration, and durable immune memory in preclinical studies. This field is required.
Let's personalize your content